BusinessaTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate UpdateBy Nasdaq OMXNov 14, 2017, 9:06 PM UTC
BusinessaTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual MeetingBy Nasdaq OMXApr 24, 2017, 12:02 PM UTC
BusinessaTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual MeetingBy Nasdaq OMXApr 24, 2017, 12:02 PM UTC
BusinessaTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual MeetingBy Nasdaq OMXApr 24, 2017, 12:02 PM UTC
